Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes - Components of Net Deferred Tax Assets (Details)

v3.25.1
Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Nov. 26, 2024
Components of net deferred tax assets      
Capitalized research and development expenses $ 22,663 $ 2,336  
Net operating loss carryforwards 36,675 30,130  
Research and development and other tax credit carryforwards 13,176 13,176  
Stock compensation 5,577 5,864  
Unearned revenue 1,250 1,984  
Royalty receivable 10,717 4,080  
Other 786 835  
Subtotal 90,844 58,405  
Less: valuation allowance (85,160) (58,326)  
Total net deferred tax assets 5,684 79  
Right-of-use assets (69) (79)  
Intangible assets (5,615)    
Total deferred tax liabilities (5,684) (79)  
Net deferred tax liabilities  
Increase (decrease) in the valuation allowance 26,800 $ 8,000  
Pulmokine      
Components of net deferred tax assets      
Total deferred tax liabilities     $ (5,659)
Increase (decrease) in the valuation allowance $ (5,700)